{"id":65239,"date":"2026-05-14T00:07:53","date_gmt":"2026-05-13T16:07:53","guid":{"rendered":"https:\/\/flcube.com\/?p=65239"},"modified":"2026-05-14T00:07:54","modified_gmt":"2026-05-13T16:07:54","slug":"merck-co-forges-four-strategic-partnerships-with-chinese-biotechs-to-advance-autoimmune-and-oncology-pipeline-through-mcicc-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65239","title":{"rendered":"Merck &amp; Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform"},"content":{"rendered":"\n<p><strong>Merck &amp; Co., Inc.<\/strong> (MSD; <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE: MRK<\/a>) has established <strong>separate strategic partnerships<\/strong> with four leading Chinese biotechnology companies\u2014<strong>Hangzhou Medimscience Biomedical Technology Co., Ltd., Degron Therapeutics Co., Ltd., Suzhou Zelgen Biopharmaceuticals Co., Ltd., and Inventisbio (Shanghai) Co., Ltd.\u2014<\/strong>to accelerate clinical development across autoimmune and oncology therapeutic areas.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-portfolio-overview\">Partnership Portfolio Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Chinese Partner<\/th><th>Therapeutic Focus<\/th><th>Modality<\/th><th>Development Stage<\/th><\/tr><\/thead><tbody><tr><td><strong>Hangzhou Medimscience Biomedical<\/strong><\/td><td>Autoimmune diseases<\/td><td>Therapeutic antibodies<\/td><td>Clinical development<\/td><\/tr><tr><td><strong>Degron Therapeutics<\/strong><\/td><td>Oncology<\/td><td>Molecular glue degraders<\/td><td>Clinical development<\/td><\/tr><tr><td><strong>Suzhou Zelgen Biopharmaceuticals<\/strong><\/td><td>Oncology<\/td><td>Trispecific antibodies<\/td><td>Clinical development<\/td><\/tr><tr><td><strong>Inventisbio (Shanghai)<\/strong><\/td><td>Undisclosed (MCICC collaboration)<\/td><td>Undisclosed<\/td><td>Early R&amp;D<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-msd-china-innovation-collaboration-center-mcicc-framework\">MSD China Innovation Collaboration Center (MCICC) Framework<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-platform-establishment\">Strategic Platform Establishment<\/h3>\n\n\n\n<p>The <strong>MSD R&amp;D China Innovation Collaboration Center (MCICC)<\/strong>, officially launched in <strong>2024<\/strong>, serves as the operational backbone for these partnerships:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mission<\/strong>: Build an <strong>open, agile, and efficient innovation collaboration platform<\/strong><\/li>\n\n\n\n<li><strong>Focus<\/strong>: High-potential projects in <strong>early research and development stages<\/strong><\/li>\n\n\n\n<li><strong>Integration model<\/strong>: Combine <strong>MSD&#8217;s global research resources<\/strong> with <strong>China&#8217;s local innovation ecosystem advantages<\/strong><\/li>\n\n\n\n<li><strong>Global ambition<\/strong>: Advance more &#8220;<strong>Created in China<\/strong>&#8221; achievements to benefit patients worldwide<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-partnership-rationale\">Partnership Rationale<\/h3>\n\n\n\n<p>Each collaboration leverages complementary strengths between MSD&#8217;s global development expertise and Chinese partners&#8217; innovative platforms:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Partnership Element<\/th><th>MSD Contribution<\/th><th>Chinese Partner Contribution<\/th><\/tr><\/thead><tbody><tr><td><strong>Global development infrastructure<\/strong><\/td><td>Regulatory expertise, international trial networks, commercial scale<\/td><td>Novel target identification, innovative modalities, local market insights<\/td><\/tr><tr><td><strong>Resource integration<\/strong><\/td><td>Funding, manufacturing capabilities, global distribution<\/td><td>Proprietary technology platforms, speed of execution, cost efficiency<\/td><\/tr><tr><td><strong>Risk sharing<\/strong><\/td><td>Development milestone payments, shared investment<\/td><td>Technology licensing, intellectual property contribution<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-therapeutic-area-specialization\">Therapeutic Area Specialization<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-autoimmune-disease-antibodies-medimscience-bio\">Autoimmune Disease Antibodies (Medimscience Bio)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target focus<\/strong>: Novel autoimmune disease targets with high unmet medical need<\/li>\n\n\n\n<li><strong>Antibody engineering<\/strong>: Leveraging Chinese partner&#8217;s proprietary antibody discovery platforms<\/li>\n\n\n\n<li><strong>Market opportunity<\/strong>: Global autoimmune therapeutics market exceeding <strong>$150 billion annually<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-oncology-molecular-glue-degraders-degron-therapeutics\">Oncology Molecular Glue Degraders (Degron Therapeutics)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology innovation<\/strong>: Molecular glue technology represents next-generation targeted protein degradation<\/li>\n\n\n\n<li><strong>Mechanism advantage<\/strong>: Potential to address &#8220;undruggable&#8221; targets through induced protein-protein interactions<\/li>\n\n\n\n<li><strong>Competitive differentiation<\/strong>: Emerging modality with significant first-mover potential<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-oncology-trispecific-antibodies-zelgen-bio\">Oncology Trispecific Antibodies (Zelgen Bio)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Format complexity<\/strong>: Trispecific antibodies enable simultaneous targeting of three distinct epitopes<\/li>\n\n\n\n<li><strong>Therapeutic rationale<\/strong>: Enhanced tumor selectivity and immune cell engagement compared to bispecific formats<\/li>\n\n\n\n<li><strong>Platform validation<\/strong>: Success would validate trispecific approach for broader oncology applications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-market-implications\">Strategic Market Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-merck-amp-co\">For Merck &amp; Co.<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline diversification<\/strong>: Access to novel modalities and targets beyond internal discovery efforts<\/li>\n\n\n\n<li><strong>China market positioning<\/strong>: Strengthened presence in rapidly growing Chinese biopharmaceutical market<\/li>\n\n\n\n<li><strong>Innovation sourcing<\/strong>: Establishes systematic approach to identify and partner with Chinese innovation leaders<\/li>\n\n\n\n<li><strong>Global competitiveness<\/strong>: Accelerates development timelines through parallel development strategies<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-chinese-biotech-ecosystem\">For Chinese Biotech Ecosystem<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>International validation<\/strong>: Partnerships with global pharma leader validate Chinese innovation quality<\/li>\n\n\n\n<li><strong>Resource access<\/strong>: Gain access to MSD&#8217;s global development infrastructure and regulatory expertise<\/li>\n\n\n\n<li><strong>Commercial pathway<\/strong>: Clear route to international markets through established pharmaceutical partner<\/li>\n\n\n\n<li><strong>Ecosystem maturation<\/strong>: Represents evolution from generic manufacturing to innovative drug discovery<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-context-amp-competitive-landscape\">Industry Context &amp; Competitive Landscape<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-china-s-biotech-evolution\">China&#8217;s Biotech Evolution<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation shift<\/strong>: Chinese companies transitioning from biosimilars to novel therapeutic modalities<\/li>\n\n\n\n<li><strong>Platform sophistication<\/strong>: Development of complex technologies like molecular glues and trispecific antibodies<\/li>\n\n\n\n<li><strong>Global ambition<\/strong>: Increasing focus on international partnerships and global market access<\/li>\n\n\n\n<li><strong>Investment momentum<\/strong>: Strong venture capital support for next-generation biotechnology platforms<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-big-pharma-china-strategy\">Big Pharma China Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Partnership proliferation<\/strong>: Major pharmaceutical companies increasingly establishing China-focused innovation centers<\/li>\n\n\n\n<li><strong>Local-global integration<\/strong>: Recognition that Chinese innovation can contribute meaningfully to global pipelines<\/li>\n\n\n\n<li><strong>Risk mitigation<\/strong>: Collaborative approach reduces development risk while maintaining access to breakthrough innovations<\/li>\n\n\n\n<li><strong>Speed advantage<\/strong>: Chinese partners often demonstrate faster execution timelines for early-stage development<\/li>\n<\/ul>\n\n\n\n<p>The establishment of these four partnerships through the MCICC platform represents a <strong>strategic commitment<\/strong> by Merck to systematically integrate Chinese innovation into its global R&amp;D pipeline, while providing Chinese biotech companies with a clear pathway to international development and commercialization.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding partnership implementation, clinical development, and commercial potential. Actual results may differ due to risks including regulatory decisions, clinical trial outcomes, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co., Inc. (MSD; NYSE: MRK) has established separate strategic partnerships with four leading&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65240,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,16,2675,176,903],"class_list":["post-65239","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-auto-immune","tag-cancer","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Merck &amp; Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck &amp; Co., Inc. (MSD; NYSE: MRK) has established separate strategic partnerships with four leading Chinese biotechnology companies\u2014Hangzhou Medimscience Biomedical Technology Co., Ltd., Degron Therapeutics Co., Ltd., Suzhou Zelgen Biopharmaceuticals Co., Ltd., and Inventisbio (Shanghai) Co., Ltd.\u2014to accelerate clinical development across autoimmune and oncology therapeutic areas.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65239\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck &amp; Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc. (MSD; NYSE: MRK) has established separate strategic partnerships with four leading Chinese biotechnology companies\u2014Hangzhou Medimscience Biomedical Technology Co., Ltd., Degron Therapeutics Co., Ltd., Suzhou Zelgen Biopharmaceuticals Co., Ltd., and Inventisbio (Shanghai) Co., Ltd.\u2014to accelerate clinical development across autoimmune and oncology therapeutic areas.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65239\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T16:07:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-13T16:07:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1303.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65239#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65239\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Merck &amp; Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform\",\"datePublished\":\"2026-05-13T16:07:53+00:00\",\"dateModified\":\"2026-05-13T16:07:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65239\"},\"wordCount\":655,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65239#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1303.webp\",\"keywords\":[\"Auto-immune\",\"Cancer\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65239#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65239\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65239\",\"name\":\"Merck &amp; Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65239#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65239#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1303.webp\",\"datePublished\":\"2026-05-13T16:07:53+00:00\",\"dateModified\":\"2026-05-13T16:07:54+00:00\",\"description\":\"Merck & Co., Inc. (MSD; NYSE: MRK) has established separate strategic partnerships with four leading Chinese biotechnology companies\u2014Hangzhou Medimscience Biomedical Technology Co., Ltd., Degron Therapeutics Co., Ltd., Suzhou Zelgen Biopharmaceuticals Co., Ltd., and Inventisbio (Shanghai) Co., Ltd.\u2014to accelerate clinical development across autoimmune and oncology therapeutic areas.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65239#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65239\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65239#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1303.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1303.webp\",\"width\":1080,\"height\":608,\"caption\":\"Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65239#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck &amp; Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck &amp; Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform - Insight, China&#039;s Pharmaceutical Industry","description":"Merck & Co., Inc. (MSD; NYSE: MRK) has established separate strategic partnerships with four leading Chinese biotechnology companies\u2014Hangzhou Medimscience Biomedical Technology Co., Ltd., Degron Therapeutics Co., Ltd., Suzhou Zelgen Biopharmaceuticals Co., Ltd., and Inventisbio (Shanghai) Co., Ltd.\u2014to accelerate clinical development across autoimmune and oncology therapeutic areas.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65239","og_locale":"en_US","og_type":"article","og_title":"Merck &amp; Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform","og_description":"Merck & Co., Inc. (MSD; NYSE: MRK) has established separate strategic partnerships with four leading Chinese biotechnology companies\u2014Hangzhou Medimscience Biomedical Technology Co., Ltd., Degron Therapeutics Co., Ltd., Suzhou Zelgen Biopharmaceuticals Co., Ltd., and Inventisbio (Shanghai) Co., Ltd.\u2014to accelerate clinical development across autoimmune and oncology therapeutic areas.","og_url":"https:\/\/flcube.com\/?p=65239","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-13T16:07:53+00:00","article_modified_time":"2026-05-13T16:07:54+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1303.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65239#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65239"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Merck &amp; Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform","datePublished":"2026-05-13T16:07:53+00:00","dateModified":"2026-05-13T16:07:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65239"},"wordCount":655,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65239#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1303.webp","keywords":["Auto-immune","Cancer","Merck Sharp &amp; Dohme","MSD","NYSE: MRK"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65239#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65239","url":"https:\/\/flcube.com\/?p=65239","name":"Merck &amp; Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65239#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65239#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1303.webp","datePublished":"2026-05-13T16:07:53+00:00","dateModified":"2026-05-13T16:07:54+00:00","description":"Merck & Co., Inc. (MSD; NYSE: MRK) has established separate strategic partnerships with four leading Chinese biotechnology companies\u2014Hangzhou Medimscience Biomedical Technology Co., Ltd., Degron Therapeutics Co., Ltd., Suzhou Zelgen Biopharmaceuticals Co., Ltd., and Inventisbio (Shanghai) Co., Ltd.\u2014to accelerate clinical development across autoimmune and oncology therapeutic areas.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65239#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65239"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65239#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1303.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1303.webp","width":1080,"height":608,"caption":"Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65239#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Merck &amp; Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1303.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65239"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65239\/revisions"}],"predecessor-version":[{"id":65241,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65239\/revisions\/65241"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65240"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}